Evidence map›Paper›PMID 39144996›Full record

ArticleHeliyon2024

Extrahepatic biliary neuroendocrine tumors: A national cancer database analysis.

Dana A Dominguez, Alyssa V Eade, John G Aversa, Brendan L Hagerty, Andrew M Blakely, Jeremy L Davis, Laleh G Melstrom, Jonathan M Hernandez

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dana A DominguezSurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Alyssa V EadeSurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
John G AversaSurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Brendan L HagertySurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Andrew M BlakelySurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Jeremy L DavisSurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Laleh G MelstromDivision of Surgical Oncology, City of Hope, Duarte, CA, USA.
Jonathan M HernandezSurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Extrahepatic biliary neuroendocrine tumors (EBNETs) are rare. We aimed to characterize EBNETs including factors associated with survival. Methods: The National Cancer Database was queried for patients with EBNETs from 2004 to 2016. Patients who underwent resection were examined using Cox proportional hazards regression and the Kaplan-Meier method. We compared overall survival (OS) among patients with EBNETs to those with NETs from other primary sites. Results: Overall, 223 patients with EBNETs were identified. Patients were predominantly male (n = 113, 50.7 %), white (n = 177, 79.4 %) and presented without distant metastasis (n = 182, 81.6 %). The majority underwent operation (n = 127, 57.9 %) with resection of the primary tumor (n = 89, 70 %). Among patients who underwent resection (n = 71), multivariable regression demonstrated older age (HR 1.11, 95 % C.I. 1.04-1.17), lymph node metastases (HR 1.19, 95 % C.I. 1.02-1.38) and poorly/undifferentiated tumors [HR 22.3, 95 % C.I. 3.78-131]) were associated with worse overall survival. Patients with EBNETs experienced abbreviated OS compared to patients with small bowel or pancreas NETs (p < 0.001), but improved OS when compared to patients with gallbladder NETs (p = 0.001). Conclusions: Tumor differentiation and lymph node status significantly impact overall survival.

Identifiers

PMID39144996
PMCPMC11320154

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.